Trials / Unknown
UnknownNCT03448055
Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health
Nutritional Intervention With the Cysteine-rich Whey Protein Isolate Dietary Supplement Immunocal® in MCI Patients: Promotion of Brain Health & Wellness During Aging and Oxidative Stress
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Immunotec Inc. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Alzheimer disease (AD) is a dementing illness characterized by progressive neuronal degeneration, gliosis, and the accumulation of intracellular inclusions and extracellular deposits of amyloid in discrete regions of the basal forebrain, hippocampus, and the association cortices. Mild cognitive impairment (MCI) refers to individuals with cognitive impairment (often memory loss) that fails to meet clinical criteria for AD or another dementing illness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Immunocal | cysteine-rich whey protein isolate |
Timeline
- Start date
- 2018-02-05
- Primary completion
- 2022-11-25
- Completion
- 2023-11-25
- First posted
- 2018-02-27
- Last updated
- 2021-02-10
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03448055. Inclusion in this directory is not an endorsement.